PD-1/PD-L1抑制剂在头颈部鳞状细胞癌治疗中的研究进展

doi:10.3760/cma.j.cn371439-20250513-00039

摘要/Abstract

摘要：

头颈部鳞状细胞癌（HNSCC）预后不良，晚期患者生存率低。免疫检查点抑制剂已成为复发/转移性HNSCC的重要治疗手段，显著改善患者预后，但仍面临原发性耐药、生物标志物异质性及免疫相关不良反应等挑战。其中，程序性死亡受体1/程序性死亡受体配体1抑制剂作为免疫疗法的核心药物，其耐药机制的多维解析是突破治疗瓶颈的核心。系统探讨程序性死亡受体1/程序性死亡受体配体1抑制剂单药及联合治疗策略在HNSCC中的研究进展，揭示肿瘤微环境中多重免疫逃逸网络的调控作用，可为解析耐药机制、指导精准治疗提供理论依据。

关键词: 头颈鳞癌, 免疫疗法, 免疫检查点抑制剂

Abstract:

Head and neck squamous cell carcinoma （HNSCC） has a poor prognosis， and the survival rate of advanced patients is low. Immune checkpoint inhibitors have become an important treatment for recurrent or metastatic HNSCC， significantly improving the prognosis of patients. However， they still face challenges such as primary drug resistance， biomarker heterogeneity， and immune-related adverse reactions. Among them， programmed death-1/programmed death-ligand 1 inhibitors serve as cornerstone agents in cancer immunotherapy； thus， a comprehensive， multi-dimensional analysis of their resistance mechanisms is essential to overcoming current treatment limitations. To systematically explore the research progress of monotherapy and combined treatment strategies of programmed death-1/programmed death-ligand 1 inhibitors in HNSCC， and to reveal the regulatory role of multiple immune escape networks in the tumor microenvironment， can provide a theoretical basis for analyzing the mechanism of drug resistance and guiding precise treatment.

Key words: Squamous cell carcinoma of head and neck, Immunotherapy, Immune checkpoint inhibitors

张奥, 崔雨. PD-1/PD-L1抑制剂在头颈部鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(4): 234-239.

Zhang Ao, Cui Yu. Research progress of PD-1/PD-L1 inhibitor in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2026, 53(4): 234-239.

参考文献 44

[1]	Filho AM, Laversanne M, Ferlay J, et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide[J]. Int J Cancer, 2025, 156(7): 1336-1346. DOI: 10.1002/ijc.35278.
[2]	Louredo BVR, Prado-Ribeiro AC, Brandão TB, et al. State-of-the-science concepts of HPV-related oropharyngeal squamous cell carcinoma: a comprehensive review[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2022, 134(2): 190-205. DOI: 10.1016/j.oooo.2022.03.016.
[3]	Gormley M, Creaney G, Schache A, et al. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors[J]. Br Dent J, 2022, 233(9): 780-786. DOI: 10.1038/s41415-022-5166-x.
[4]	Colevas AD, Cmelak AJ, Pfister DG, et al. NCCN guidelines^® insights: head and neck cancers, version 2.2025[J]. J Natl Compr Canc Netw, 2025, 23(2): 2-11. DOI: 10.6004/jnccn.2025.0007.
[5]	Schulz D, Feulner L, Santos Rubenich D, et al. Subcellular localization of PD-L1 and cell-cycle-dependent expression of nuclear PD-L1 variants: implications for head and neck cancer cell functions and therapeutic efficacy[J]. Mol Oncol, 2024, 18(2): 431-452. DOI: 10.1002/1878-0261.13567. pmid: 38103190
[6]	杨扬, 范典, 郑博豪, 等. 免疫代谢在肿瘤免疫中的功能研究进展[J]. 四川大学学报(医学版), 2023, 54(3): 497-504. DOI: 10.12182/20230560304.
[7]	Ge J, Meng Y, Guo J, et al. Human papillomavirus-encoded circular RNA circE7 promotes immune evasion in head and neck squamous cell carcinoma[J]. Nat Commun, 2024, 15(1): 8609. DOI: 10.1038/s41467-024-52981-4. pmid: 39366979
[8]	Chen X, Lu Q, Zhou H, et al. A membrane-associated MHC-Ⅰ inhibitory axis for cancer immune evasion[J]. Cell, 2023, 186(18): 3903-3920. DOI: 10.1016/j.cell.2023.07.016.
[9]	陈燕, 胡泽楠, 姜雷. 乳酸对肿瘤免疫微环境及免疫治疗影响的研究进展[J]. 中国肿瘤临床, 2025, 52(8): 407-412. DOI: 10.12354/j.issn.1000-8179.2025.20250102.
[10]	Duan YF, Dai JH, Lu YQ, et al. Disentangling the molecular mystery of tumour-microbiota interactions: microbial metabolites[J]. Clin Transl Med, 2024, 14(11): e70093. DOI: 10.1002/ctm2.70093.
[11]	Mustafa S, Koran S, AlOmair L. Insights into the role of matrix metalloproteinases in cancer and its various therapeutic aspects: a review[J]. Front Mol Biosci, 2022, 9: 896099. DOI: 10.3389/fmolb.2022.896099.
[12]	Feng B, Wu J, Shen B, et al. Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures[J]. Cancer Cell Int, 2022, 22(1): 166. DOI: 10.1186/s12935-022-02599-7. pmid: 35488263
[13]	Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 393(10167): 156-167. DOI: 10.1016/S0140-6736(18)31999-8. pmid: 30509740
[14]	Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. pmid: 31679945
[15]	Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19): 1856-1867. DOI: 10.1056/NEJMoa1602252.
[16]	Gillison ML, Blumenschein G, Fayette J, et al. Long-term outcomes with nivolumab as first-line treatment in recurrent or metastatic head and neck cancer: subgroup analysis of checkmate 141[J]. Oncologist, 2022, 27(2): e194-e198. DOI: 10.1093/oncolo/oyab036. pmid: 35641218
[17]	U.S. Food & Drug Administration. Nivolumab for SCCHN[EB/OL]. (2016-11-10) [2025-10-10]. https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-scchn.
[18]	Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase Ⅱ study in patients with≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy[J]. Eur J Cancer, 2019, 107: 142-152. DOI: 10.1016/j.ejca.2018.11.015. pmid: 30576970
[19]	Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase Ⅲ study[J]. Ann Oncol, 2020, 31(7): 942-950. DOI: 10.1016/j.annonc.2020.04.001. pmid: 32294530
[20]	Colevas AD, Bahleda R, Braiteh F, et al. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase Ⅰ trial[J]. Ann Oncol, 2018, 29(11): 2247-2253. DOI: 10.1093/annonc/mdy411. pmid: 30219915
[21]	Haddad R, Fayette J, Teixeira M, et al. Atezolizumab in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomized clinical trial[J]. JAMA, 2025, 333(18): 1599-1607. DOI: 10.1001/jama.2025.1483. pmid: 40079944
[22]	Alwithenani A, Hengswat P, Chiocca EA. Oncolytic viruses as cancer therapeutics: from mechanistic insights to clinical translation[J]. Molecular Therapy, 2025, 33(5): 2217-2228. DOI: 10.1016/j.ymthe.2025.03.035.
[23]	伊萌, 杨全军, 琚姝, 等. 溶瘤病毒调控肿瘤微环境及联合治疗的研究进展[J]. 系统医学, 2022, 7(21): 191-194. DOI: 10.19368/j.cnki.2096-1782.2022.21.191.
[24]	Chen F, Lang L, Yang J, et al. SMAC-armed oncolytic virotherapy enhances the anticancer activity of PD1 blockade by modulating PANoptosis[J]. Biomark Res, 2025, 13(1): 8. DOI: 10.1186/s40364-025-00726-w. pmid: 39789615
[25]	Song J, Yang P, Chen C, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance[J]. Signal Transduct Target Ther, 2025, 10(1): 219. DOI: 10.1038/s41392-025-02266-z.
[26]	Zhuang H, Yu B, Tao D, et al. The role of m⁶A methylation in therapy resistance in cancer[J]. Mol Cancer, 2023, 22(1): 91. DOI: 10.1186/s12943-023-01782-2. pmid: 37264402
[27]	Bhatia A, Burtness B. Treating head and neck cancer in the age of immunotherapy: a 2023 update[J]. Drugs, 2023, 83(3): 217-248. DOI: 10.1007/s40265-023-01835-2. pmid: 36645621
[28]	Wang H, Hu L, Zhang F, et al. An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC[J]. Oral Oncol, 2024, 153: 106814. DOI: 10.1016/j.oraloncology.2024.106814.
[29]	Chen TH, Chang PM, Yang MH. Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer[J]. J Chin Med Assoc, 2021, 84(4): 361-367. DOI: 10.1097/JCMA.00000000000 00497.
[30]	Saba NF, Steuer CE, Ekpenyong A, et al. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial[J]. Nat Med, 2023, 29(4): 880-887. DOI: 10.1038/s41591-023-02275-x. pmid: 37012550
[31]	郭晔, 张陈平. 复发/转移性头颈部鳞癌免疫检查点抑制剂治疗专家共识(2024年版)[J]. 中国癌症杂志, 2024, 34(4): 425-438. DOI: 10.19401/j.cnki.1007-3639.2024.04.010.
[32]	刘海英, 赵广章, 崔巍, 等. 局部晚期头颈鳞状细胞癌诱导免疫治疗联合化疗探索研究[J]. 中国耳鼻咽喉头颈外科, 2023, 30(5): 287-291. DOI: 10.16066/j.1672-7002.2023.05.004.
[33]	Shi Y, Guo W, Wang W, et al. Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial[J]. Nat Med, 2024, 30(9): 2568-2575. DOI: 10.1038/s41591-024-03110-7. pmid: 38942993
[34]	Marangoni F, Zhakyp A, Corsini M, et al. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop[J]. Cell, 2021, 184(15): 3998-4015.e19. DOI: 10.1016/j.cell.2021.05.027. pmid: 34157302
[35]	Ferrarotto R, Bell D, Rubin ML, et al. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8⁺ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results[J]. Clin Cancer Res, 2020, 26(13): 3211-3219. DOI: 10.1158/1078-0432.CCR-19-3977. pmid: 32269052
[36]	Schoenfeld JD, Hanna GJ, Jo VY, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1563-1570. DOI: 10.1001/jamaoncol.2020.2955.
[37]	Machiels JP, Tao Y, Licitra L, et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2024, 25(5): 572-587. DOI: 10.1016/S1470-2045(24)00100-1.
[38]	Yu Y, Lee NY. JAVELIN head and neck 100: a phase Ⅲ trial of avelumab and chemoradiation for locally advanced head and neck cancer[J]. Future Oncol, 2019, 15(7): 687-694. DOI: 10.2217/fon-2018-0405.
[39]	Weiss J, Sheth S, Deal AM, et al. Concurrent definitive immuno-radiotherapy for patients with stage Ⅲ-Ⅳ head and neck cancer and cisplatin contraindication[J]. Clin Cancer Res, 2020, 26(16): 4260-4267. DOI: 10.1158/1078-0432.CCR-20-0230.
[40]	Tao Y, Biau J, Sun XS, et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase Ⅱ trial[J]. Ann Oncol, 2023, 34(1): 101-110. DOI: 10.1016/j.annonc.2022.10.006.
[41]	Wang S, Yan L, Yu J, et al. Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis[J]. Eur Arch Otorhinolaryngol, 2024, 281(7): 3385-3395. DOI: 10.1007/s00405-024-08517-z. pmid: 38358507
[42]	Rached L, Laparra A, Sakkal M, et al. Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations[J]. Cancer Treat Rev, 2024, 127: 102751. DOI: 10.1016/j.ctrv.2024.102751.
[43]	倪军, 张力. 肿瘤免疫治疗相关不良反应研究进展[J]. 中华内科杂志, 2021, 60(1): 84-89. DOI: 10.3760/cma.j.cn112138-20200308-00204.
[44]	Hu M, Lin X, Sun T, et al. Gut microbiome for predicting immune checkpoint blockade-associated adverse events[J]. Genome Med, 2024, 16(1): 16. DOI: 10.1186/s13073-024-01285-9. pmid: 38243343